Intravenous belimumab plus SOC vs placebo plus SOC was not linked to an increased risk for infection among patients with SLE.

Cullinan's innovative approach and Zipalertinib's potential approval in 2026 position it as a promising biotech investment.

At cloud-based human capital management company Dayforce, adding WellTheory's specialized support to their benefits in ...

Lumos Diagnostics shares today soared by more than 150pc after the company unveiled a US distribution deal worth as much as ...

Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended June 30, 2025, before the market opens on Tuesday, July 29, 2025.

Last week Tuesday, PureTech had announced that Raju Kucherlapati stepped down immediately as chair and was replaced by Sharon Barber-Lui, who will be interim chair and also lead the process for ...

Your immune system is supposed to protect you from viruses, bacteria, and other harmful invaders. However, when you have an ...

Noxopharm Ltd (ASX:NOX) has got its HERACLES trials out the gates in Week 29, dosing a preliminary patient in the ...